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Abstract
AIM: The pathogenesis of hypogonadism in liver cirrhosis
is not well understood. Previous results from our laboratory
showed that IGF-1 deficiency might play a pathogenetic
role in hypogonadism of cirrhosis. The administration of
IGF-1 for a short period of time reverted the testicular
atrophy associated with advanced experimental cirrhosis.
The aim of this study was to establish the historical
progression of the described alterations in the testes,
explore testicular morphology, histopathology, cellular
proliferation, integrity of testicular barrier and hypophyso-
gonadal axis in rats with no ascitic cirrhosis.
METHODS: Male Wistar rats with histologically-proven
cirrhosis induced with carbon tetrachloride (CCl4) for 11 wk,
were allocated into two groups (n = 12, each) to receive
recombinant IGF-1 (2 µg/100 g·d, sc) for two weeks or
vehicle. Healthy rats receiving vehicle were used as control
group (n = 12).
RESULTS: Compared to controls, rats with compensated
cirrhosis showed a normal testicular size and weight and
very few histopathological testicular abnormalities.
However, these animals showed a significant diminution
of cellular proliferation and a reduction of testicular
transferrin expression. In addition, pituitary-gonadal axis
was altered, with significant higher levels of FSH (P<0.001
vs controls) and increased levels of LH in untreated cirrhotic
animals. Interestingly, IGF-1 treatment normalized testicular
transferrin expression and cellular proliferation and reduced
serum levels of LH (P = ns vs controls, and P<0.01 vs
untreated cirrhotic group).
CONCLUSION: The testicular barrier is altered from an
early stage of cirrhosis, shown by a reduction of transferrin
expression in Sertoli cells, a diminished cellular proliferation
and an altered gonadal axis. The treatment with IGF-1
could be also useful in this initial stage of testicular disorder
associated with compensated cirrhosis.
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INTRODUCTION
Hypogonadism (characterized by low testosterone levels and
relative hyperestrogenism, loss of libido, sexual impotence
and feminine body features in men) is a common complication
of advanced liver cirrhosis[1]. Previous data demonstrated that
rats with advanced cirrhosis showed reduced testicular size and
weight and severe histopathological testicular abnormalities,
including reduced tubular diameters, loss of the germinal line,
and diminutions in cellular proliferation and spermatogenesis
and testicular transferrin expression, a good marker of the integrity
of blood-testis barrier[2]. In addition, low serum testosterone and
high serum LH were present in cirrhotic animals, as well as
decreased levels of serum IGF-1. Interestingly, the administration
of IGF-1 at low doses for a short period of time reverted the
testicular atrophy and improved the altered pituitary-testicular
axis in these animals[2]. In cirrhotic patients, hypogonadism
has been attributed to a variety of mechanisms including
gonadal toxicities of alcohol, malnutrition and increased
production of estrogens from androgens in peripheral tissues
due to the existence of portal systemic shunting[3-9].
        Insulin-like growth factor-1 (IGF-1) is an anabolic hormone
produced in different tissues although the liver accounts for
90% of the circulating hormone, which is synthesized in response
to growth hormone (GH) stimulation[10,11]. In cirrhosis the
reduction of receptors for GH in hepatocytes and the diminished
synthesizing ability of the liver parenchyma caused a progressive
fall of serum IGF-1 levels[11-14]. Although in an early stage of cirrhosis
serum levels of IGF-1 were normal, its bio-availability seemed to
be diminished[15]. The clinical impact of the reduced production
or availability of IGF-1 in cirrhosis was largely unknown[11-14].
Recent studies from our laboratory have demonstrated that
short courses of treatment with low doses of IGF-1 were able
to induce marked improvements in nutritional state[15], nitrogen
retention[16], intestinal absorption[17-19], osteopenia[20,21], liver
function reducing fibrogenesis[22,23], and restore the reduced
somatostatinergic tone[24] in rats with experimental cirrhosis.
These data suggest that IGF-1 deficiency plays a pathogenetic
role in several systemic complications occurring in cirrhosis.
       It is well known that IGF-1 stimulates testosterone synthesis
and spermatogenesis[25-32]. Its deficiency could contribute to the
development of hypogonadism associated with cirrhosis as
the previous data supported[2]. Since the pathogenesis of
hypogonadism in cirrhosis is not yet well understood, the aim of
the present study was to study the chronological progression of
the described alterations in testes[2] in advanced cirrhosis, explore
testicular morphology, histopathology, cellular proliferation,
integrity of testicular barrier and hypophyso-gonadal axis in rats
with cirrhosis in an early stage, without ascites.
MATERIALS AND METHODS
Induction of liver cirrhosis
All experimental procedures were performed in conformity with
The Guiding Principles for Research Involving Animals[33].
Cirrhosis was induced as previously described[15,16]. Briefly,
male Wistar rats (3-week-old, 130-150 g) were subjected to CCl4
inhalation (Merck, Darmstadt, Germany) twice a week for 11 wk
with a progressively increasing exposure time from 1 to 5 min.
During the whole period of cirrhosis induction animals received
Phenobarbital (Luminal, Bayer, Leverkusen, Germany) in the
drinking water (400 mg/L). Both food (standard semipurified
diet for rodents; B.K. Universal, Sant Vicent del Horts, Spain)
and water were given ad libitum. Healthy, age and sex-matched
control rats were maintained under the same conditions but
receiving neither CCl4 nor Phenobarbital.
Study design
The treatment was administrated for 2 wk after stopping of CCl4
exposure. In the morning of d 0, animals were weighed and
blood samples were drawn from the retroocular venous plexus
from all rats with capillary tubes (Marienfeld, Germany) and
stored at -20 °C until used for analytical purposes. Cirrhotic
rats were randomly assigned to receive either vehicle (saline)
(group CI, n = 12) or recombinant human IGF-1 (Pharmacia-
Uppsala, Sweden) (2 µg/100 g·d in two divided doses,
subcutaneously) (group CI+IGF, n = 12) for two weeks. Control
rats (group CO, n = 10) received saline during the same period.
      In the morning of the 15th d, rats were weighed, blood was
obtained from the retroocular plexus and animals were killed by
decapitation. After the abdominal cavity was opened, the liver
and testes were dissected and weighed. Samples from the left
major liver lobe and testes were processed for histological
examination (fixed in Bouin’s solution). The testicular diameters
(AP and LM) were measured using a precision calliper,
Mituyoto® (±0.05 mm). Ascites was ruled out by direct
exploration of abdominal cavity in all cirrhotic animals.
Liver histopathology
Bouin-fixed tissues were processed and sections (4-µm) were
stained with Haematoxylin and Eosin and Masson’s trichrome.
Livers were scored (1 to 4) as previously reported[15,22].
Preestablished criteria for inclusion of cirrhotic (CI) animals in
the final analysis were the presence of: (1) altered baseline
biochemical data of liver function; and (2) in retrospect,
histologically proven liver cirrhosis (scores 3 or 4 of the
classification) in CCl4-treated-animals. All animals had
compensated cirrhosis without ascites.
Testicular histopathology and PCNA and transferrin immuno-
histochemistry
For histopathological evaluation of testes, 30 seminiferous
tubules from each rat of the three groups were blindly evaluated
by two observers and the arithmetic mean of the scores was
taken as the final result. Transverse sections of seminiferous
tubuli were examined and evaluation of histological changes
was made using a light projection microscope (Micro Promar
Leitz GMBH, Wetzlar, Germany) at 150× magnification. The
following parameters were studied: tubular diameter,
quantitation of the presence of different types of cells in tubuli,
presence of peritubular fibrosis, and the number of proliferating
cells. For general purposes haematoxylin & eosin stain and
Masson’s trichrome stain were used. Specific techniques for
other purposes are specified in the corresponding paragraphs.
       Changes in tubuli were classified into 5 categories (Category
I: highest damage to Category V: full normality). Category I:
presence of only Sertoli cells; category II: Sertoli cells plus
spermatids; category III: Sertoli cells, plus spermatides, and
spermatocytes; category IV: presence of all kinds of cells but
showing some morphological alterations (i.e.: severe
vacuolization, aberrant cells); category V: presence of all kinds
of cells without morphological alterations. The presence of
peritubular fibrosis was evaluated in Masson’s trichrome
preparations according to the thickness of the staining of
collagen deposition surrounding tubuli. Proliferating cells were
identified by immunostaining of proliferating cellular nuclear
antigen (PCNA) using an avidin-biotin peroxidase method[34]
with retrieval of antigen by means of microwave irradiation.
Specific anti-PCNA antibody (mouse anti-PCNA, clone PC 10,
DAKO, Denmark) biotinylated rabbit anti-mouse IgG (DAKO,
Denmark) were used and the avidin-biotin complex technique
(ABC, DAKO kit) was performed. The bound antibodies were
visualized by means of 3,3’-diaminobenzidine tetrahydrochloride
(Sigma Chemical Company, St. Louis, MO) with nickel
enhancement[34]. Finally, samples were slightly counterstained
(10 s) in hematoxylin, dehydrated, and mounted in DPX.
Controls were performed by substitution of the primary
antibody by TBS. The number of PCNA positive cells was
recorded. The result was expressed as stained cells per tubuli
(arithmetic mean of 30 screened tubuli).
      In addition, the expression of transferrin[35] in tubuli was
evaluated by immunostaining using similar technique as for
PCNA with specific anti-transferrin antibody (obtained from
rabbit, RARa/TRf, Nordic Immunological Laboratories,
Teknovas, The Netherland). Transferrin expression was scored
from 0 to 4 points. If 30 tubuli expressed transferrin normally all
over the germinal epithelium, it was scored 0 points. The
remaining scores were obtained according to the following
formula: (30-tubuli showing expression of transferrin all over
the germinal epithelium) ×0.075.
Analytical methods
Serum levels of albumin, total proteins, glucose, cholesterol,
bilirubin, alkaline phosphatase, transferrin and aminotransferases
(AST and ALT) were determined by routine laboratory methods
using a Hitachi 747 autoanalyzer (Boerhringer-Mannheim,
Germany). Serum levels of the different hormones were assessed
by RIA in a GammaChen 9612 Plus (Serono Diagnostics, Roma,
Italy) using specific commercial assay systems: total and free
testosterone and estradiol-6, Coat-a-Count, DPC (Diagnostic
Products Corporation, Los Angeles, CA); rat luteinizing hormone
(rLH) and rat follicle stimulating hormone (rFSH) from Amersham
International Plc (Little Chalfont Buckinghamshire, England HP7
9NA); IGF-1 by extraction (Nichols Institute Diagnostics, San
Juan Capistrano, CA, USA).
Lipid peroxidation assessment of testicular homogenates
Malondyaldehyde (MDA) was assessed after heating samples
at 45  for 60 min in acid medium. It was quantitated by a
colorimetric assay using LPO-586 (Bioxytech; OXIS International
Inc., Portland, OR, USA), which after reacting with MDA,
generated a stable chromophore that could be measured at
586 nm (Hitachi U2 000 Spectro; Roche).
Statistical analysis
Data are expressed as mean±SE. To assess the homogeneity
between the three groups of rats a Kruskall-Wallis test was
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used, followed by multiple post-hoc comparisons using Mann-
Withney U tests (two tailed) with Bonferroni adjustment. A
regression model was fitted considering histopathological score,
PCNA or transferrin expression scores and IGF-1 plasma
concentration as the dependent and independent variables
respectively. Within group differences between pre-and post-
treatment values were assessed by means of Wilcoxon matched
pairs signed rank sum test. Any P value less than 0.05 was
considered to be statistically significant. Calculations were
performed by SPSS Win v.6.0. program.
RESULTS
At baseline, CI groups showed abnormal values compared to
controls (CO) in serum levels of alanine aminotransferase
(CO = 26±2; CI = 273±49 IU/L, P<0.01), aspartate aminotransferase
(CO = 55±5; CI = 297±49 IU/L, P<0.001), cholesterol (CO = 82±4;
CI = 115±5 mg/dL, P<0.05), alkaline phosphatase (CO = 310±43;
CI = 701±146 IU/L,  P<0.05), bilirubin (CO = 0.4±0.0; CI = 1.2±0.3 mg/dL,
P<0.05), total proteins (CO = 6.9±0.1; CI = 6.4±0.2 g/dL, P<0.05)
and albumin (CO = 3.6±0.1; CI = 3.1±0.2 g/dL, P<0.05). No
differences were found between cirrhotic groups.
      At the end of the experimental period, all rats from groups
CI and CI+IGF showed established cirrhosis (mixed micro-
macronodular cirrhosis in liver histopathology) with some signs of
portal hypertension (spleen weight, g, CO = 0.8±0.0; CI = 1.4±0.2;
CI+IGF = 1.4±0.1, P<0.001 both cirrhotic groups vs controls).
Ascites was absent in all of the cirrhotic animals.
Testicular morphology and morphometry
The testicular size and volume were normal in the cirrhotic
groups as compared to controls. Morphometric study showed
reduction in testicular weight (in absolute values but not if it
was corrected by body mass) in untreated cirrhotic group as
compared to controls and CI+IGF group. Findings regarding
longitudinal and transverse testicular diameters were similar to
those in testicular weight. Morphometric data in the three
groups are summarized in Table 1.
Testicular histopathology
Figure 1 shows testicular morphology in the three experimental
groups. Testicular histological section of normal rat (CO)
demonstrated active spermatogenesis in normal-size
seminiferous tubuli with thin basement membranes and minimal
peritubular fibrosis. Leydig cells were scarce, being widely
separated by seminiferous tubuli. No evidence of peritubular
fibrosis and other alterations was found in cirrhotic groups.
Cellular analyses (see Methods) in 30 seminiferous tubuli were
performed in each preparation and summarized in Table 2. No
relevant findings were obtained in this morphologic study.
       Testicular cellular proliferation, as evaluated by PCNA[35],
was significantly reduced in CI rats while CI+IGF rats showed
values similar to controls (CO: 66±2, CI: 57±1, CI+IGF: 61±1,
P<0.001 untreated cirrhotic group vs controls and P<0.05
CI+IGF vs controls and CI group). Figure 2 shows PCNA
immunohistochemistry (PCNA+cells) in the three groups.
       Testicular transferrin, a marker of the integrity of hemato-
testicular barrier[36-38], was evaluated from 0 to 4 points by
immunohistochemistry in testicular slices (see Methods).
Transferrin expression was decreased in CI rats (3.40±0.03
points, P<0.001 vs CO and CI+IGF groups) as compared to
controls (3.98±0.04 points) and to cirrhotic rats receiving IGF-1
(3.76±0.05 points). Figure 3 shows transferrin expression in the
three experimental groups.
      Testicular levels of MDA in order to study the likely direct
damage of CCl4 to testes, MDA levels, an index of lipid
peroxidation[39],  were assessed in testicular homogenates. No
differences were found between the three experimental groups
in testicular MDA content (nmoL/mg protein, CO = 9.1±0.8,
CI = 13.0±3.2, CI+IGF =  8.9±1.6).
Pituitary-gonadal axis
Serum levels of sexual hormones are summarized in Table 3. No
significant differences were found between groups, either in
total and free testosterone, or estradiol, or in the ratio of estradiol/
testosterone. However, a significant increase of FSH (P<0.001
vs controls) and also high levels of LH (P = 0.06 vs controls)
were observed in untreated rats with compensated cirrhosis,
suggesting an altered negative feed-back since this early stage
of the cirrhosis. On the other hand, LH concentrations were
moved towards normal values in IGF-1 treated cirrhotic group
(P = ns vs controls, and P<0.01 vs untreated cirrhotic rats).
Serum levels of IGF-1
At the time of animal sacrifice (d 15), no significant differences
between the three groups were found in serum levels of IGF-1
(CO: 1030±67, CI: 1165±58, CI+IGF: 1030±38 ng/mL), similar to
those described previously in early stage of cirrhosis[16-18,24].
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Table 1  Body mass and parameters of testicular size and weight in the three experimental groups (d 15)
   Healthy control rats    Untreated cirrhotic rats  Cirrhotic rats treated with IGF-1
           (CO, n = 12)   (CI, n = 12)    (CI+IGF, n=12)
Body mass (g) 545.0±1.0   460.0±1.0d        458.0±9.0d
Right testis (g)    2.0±0.0       1.6±0.1d                 1.7±0.1d
(×100 g/bm)   (0.4±0.0)      (0.3±0.0)           (0.4±0.0)
External testicular diameters (mm)
•  Longitudina               20.4±0.26                 18.56±0.22d           18.37±0.34d
•  Transversal               10.3±0.24                   9.41±0.23b              9.64±0.14a
aP<0.05; bP<0.01; dP<0.001 vs CO group.
Table 2  Cellular analysis: Thirty seminiferous tubuli were examined in each preparation. The table summarizes the number of
tubuli in each category: category I, only Sertoli s cells; category II, I+spermatids; category III, II+spermatocytes; category IV, all
types of cells but with some alterations; category V, all types of cells with normal features
Category I              II            III IV   V
Controls (CO) (n = 10)×30 tubuli 0  0 0   2 298
Untreated cirrhotic rats (CI) (n = 10)×30 tubuli 0  0 5 20 275
IGF-treated cirrhotic rats (CI+IGF) (n = 10)×30 tubuli 0  0 0   8 292
Statistical analysis (P) ns ns ns         aP<0.05   ns
aP<0.05, CI vs CO group.
Table 3  The pituitary-gonadal axis (on d 15) in the three experimental groups
                   Healthy control rats                Untreated cirrhotic rats       IGF-1-treated cirrhotic rats
            (CO, n = 12) (CI, n = 12)    (CI+IGF, n = 12)
Total testosterone (ng/dL)     62±13     77±17  64±7
Free testosterone (pg/mL)  0.36±0.09  0.36±0.10           0.41±0.05
Estradiol (pg/mL)     31±2     33±2  29±1
Estradiol/Total testosterone    0.5±0.1    0.5±0.1 0.6±0.1
LH (ng/mL)    4.8±0.6    6.0±0.5 3.8±0.7d
FSH (ng/mL)     22±8     27±1f  26±4b
bP<0.01CI+IGF vs CO group; dP<0.01 CI+IGF vs CI group; fP<0.001 CI vs CO group.
Figure 1  Microscopy of testes (×150 magnification, Masson’s stain). Testicular histological sections of normal rat (CO) demon-
strated active spermatogenesis in normal-size seminiferous tubuli with thin basement membranes and minimal peritubular
fibrosis. Leydig cells were scarce, being widely separated by seminiferous tubuli. No evidence of peritubular fibrosis and other
alterations were found in testes from cirrhotic animals.
Figure 2  Study of proliferative activity, assessed by PCNA immunostaining. A significant reduction of cellular proliferation were
observed in rats with compensated cirrhosis. This reduction was normalized in IGF-1 treated cirrhotic group (CI+IGF). (×200
magnification, in the three pictures).
Figure 3 Immunohistochemistry for testicular transferrin in seminiferous tubuli. Transferrin immunostaining was observed at the
level of Sertoli cells and in germ cells in normal rats (CO) and in cirrhotic rats treated with IGF-1 (CI+IGF) but a lower or absent
transferrin immunostaining was observed in several tubuli of untreated cirrhotic rats (CI) (score, CI: 3.40±0.03, CO: 3.98±0.04,
CI+IGF-1: 3.76±0.05).
DISCUSSION
This study demonstrates that rats with compensated CCl4-
induced cirrhosis show some testicular alterations and gonadal
dysfunction, from early stages of liver cirrhosis. The main finding
of this study is that there is an altered hemato-testicular barrier,
probably responsible for the reduction of cellular proliferation,
as well as a paradoxical response of pituitary-testicular axis.
      The occurrence of testicular atrophy and gonadal dysfunction
in advanced cirrhosis is a well known clinical event[1,3-9]. Both
testicular histopathological abnormalities and low levels of
serum testosterone have been described in patients with
CO Cl C I-IGF
CO Cl CI-IGF
CO Cl CI-IGF
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alcoholic and nonalcoholic cirrhosis several years ago[3-9].
Previous experimental data[2] showed that severe testicular
atrophy and gonadal insufficiency treated with low doses of
IGF-1 recovered to normal in a very short time (21 d). Data
regarding experimentally induced cirrhosis are, however, scarce.
Our previous data showed a severe testicular damage[2] as
manifested by macroscopic testicular atrophy and a variety of
histopathological abnormalities including a reduction in
tubular diameters, presence of aberrant cells in tubular lumen,
peritubular fibrosis, loss of the germinal line and a marked
reduction in cellular proliferation. These alterations resembled
those found in necropsic studies in alcoholic cirrhotics[1] and
those reported in experimental models of testicular damage such
as chronic testicular ischemia[35].
      The mechanisms responsible for the described alterations
are not fully understood, although the relationship between
IGF-1 deficiency and testicular damage in cirrhosis was
demonstrated in the mentioned work[2]. In cirrhotic rats included
in the current work, no IGF-1 deficiency was present but there
was a reduced availability of this hormone as it has been suggested
previously[16-18,22]. Moreover, we have previously demonstrated
that the changes induced by cirrhosis in the serum profile of
IGF-1 binding proteins further reduce bio-availability of IGF-1
in cirrhotic rats[16]. In fact, exogenous administration of IGF-1
was able to reverse several abnormalities (decreased food utility
and intestinal absorption of nutrients, and somatostatinergic
tone and osteopenia) associated with cirrhosis in animals with
normal serum levels of this hormone[16-20,22-24].
       On the other hand, a direct effect of IGF-1 on testes seemed
to be the most important factor to explain previous findings[2].
This idea is supported by the existence of receptors for IGF-1
in Sertoli cells, germ cells and Leydig cells[25-27] and by findings
demonstrating a direct effect of IGF-1 on testes[27-31]. Since
IGF-1 is a well recognized trophic factor for testis, its deficiency
could be a contributing factor to testicular damage in cirrhosis.
      The present work was designed in order to gain more insights
into the mechanisms involved in the pathogenesis of
hypogonadism associated with liver cirrhosis. In fact, many
factors that have been involved in this process, such as portal
systemic shunting[1,39,40] or undernutrition[1,41] were minimized
in this early stage of the liver disease. Specifically, this study
was targeted to establish the historical progression of the
described testicular alterations[2].
      The blood-testis barrier is considered nearly as specific as
the blood-brain barrier[42]. Although all cells require irons from
serum transferrin produced by hepatocytes, cells that create a
blood barrier such as Sertoli cells in the testis and choroid
plexus epithelium in the brain also express the transferrin gene
to provide irons to cells sequestered within the serum-free
environment. Testicular transferrin expression was a good
marker of the integrity of the hemato-testicular barrier[36,37].  A
major finding of this work was that transferrin expression by
Sertoli cells was reduced in untreated cirrhotic rats. The medical
bioavailability of IGF-1 could be due to the mechanism of
testicular transferrin reduction. IGF-1 treatment increased the
expression of this protein in Sertoli cells of cirrhotic rats (Figure 3).
This possibility seemed to be plausible since several metabolic
functions of Sertoli cells were also influenced by IGF-1[32,43-45].
Interestingly, the recovery of transferrin expression in Sertoli
cells observed in our study suggested a role for IGF-1 in
maintaining the integrity of the hematotesticular barrier[2,33-38].
     The first step of the pathogenesis of testicular atrophy
occurring in advanced cirrhosis seems to be the decreased
expression of transferrin, showing a dysfunction of Sertoli cells
and consequently the disruption in blood-testis barrier
integrity. Therefore, the observed reduction of cellular
proliferation finally affecting spermatogenesis[2,46] would be its
logical consequence.
      A question arises as to whether direct toxicity of CCl4 on
testicular tissue could contribute to testicular injury. Alcohol
was known to produce oxidative damage and to be able to pass
across testicular barrier[47,48]. This toxic possibility has been
reasonably ruled out by the presence of similar levels of MDA,
a marker of lipid peroxidation[39], in testicular homogenates from
the three experimental groups. Certainly, a slight increase of
testicular MDA was found in untreated cirrhotic rats, but this
did not reach statistical significance.
       In the early stage of cirrhosis, testosterone levels were normal.
However, both FSH and LH were increased in untreated cirrhotic
animals. This abnormal response of the negative feedback could
be an initial hormonal reaction of primary hypogonadism. In
advanced stages of cirrhosis, we found increased levels of
serum LH associated with a significant reduction of total and
free serum testosterone defining a picture of primary
hypogonadism, thus ruling out hypothalamic-pituitary
dysfunction as the responsible mechanism[2]. Interestingly,
LH levels were reduced by IGF-1 treatment in this series with
compensated cirrhosis and an incipient gonadal dysfunction.
The significant increase of FSH could be related to the
observed reduction of cellular proliferation in cirrhotic rats.
Since a close relationship has been reported between IGF-1 and
gonadotropins[49-51], our findings require further investigation.
      In summary, this study shows an altered hemato-testicular
barrier from an early stage of cirrhosis and suggests that the
reduction of IGF-1 bioavailability may play a critical role in the
beginning stage of testicular damage and hypogonadism
associated with liver cirrhosis. In addition, these results support
the conclusion that the exogenous administration of IGF-1 may be
useful for the treatment of testicular alterations in cirrhotic patients.
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